Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients

European Journal of Cancer

Volumn 44, Issue 12, 2008, Pages 1678-1683

  Zafra, Marta ^a   Ayala, Francisco ^a   Gonzalez Billalabeitia, Enrique ^a   Vicente, Elena ^a   Gonzalez Cabezas, Pedro ^b   García, Teresa ^a   Macías, José A ^a   Vicente, Vicente ^a  

^a HOSPITAL MORALES MESEGUER   (Spain)

^b Clinica Mediterranea de Neurociencias   (Spain)

Author keywords

Disease management; Medical Oncology; Neoplasm; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY PET; CHILD; EVALUATION; LYMPH NODE; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; WHOLE BODY IMAGING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 48449083331     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.05.021     Document Type: Article

References (21)

1. Kelloff G.J., Hoffman J.M., Johnson B., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11 (2005) 2785-2808
2. Facey K., Bradbury I., Laking G., and Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11 iii-iv (2007) xi-267
3. Rodriguez-Garrido M., and Asensio del Barrio C. Multicentre assessment and monitored used of [(18)F] FDG-PET in oncology: the Spanish experience. Eur J Nucl Med Mol Imaging 35 (2008) 296-304
4. Yap C.S., Seltzer M.A., Schiepers C., et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 42 (2001) 1334-1337
5. Meta J., Seltzer M., Schiepers C., et al. Impact of whole-body 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 42 (2001) 586-590
6. Talbot J.N., Montravers F., Grahek D., Kerrou K., Gutman F., and Cailleux N. FDG PET and its impact on patient's management in oncology. Presse Med 35 (2006) 1339-1346
7. Gutte H., HǾjgaard L., and Kjaer A. Early clinical experience and impact of 18F-FDG PET. Nucl Med Commun 26 (2005) 989-994
8. Gopalan D., Griffiths D., Townsend C., et al. Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrer's perspective. Nucl Med Commun 23 (2002) 1041-1046
9. Gutte H., HǾjgaard L., and Kjaer A. Early clinical experience and impact of 18F-FDG PET. Nucl Med Commun 26 (2005) 989-994
10. Partridge S., Timothy A., O'Doherty M.J., Hain S.F., Rankin S., and Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-d glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 11 (2001) 1273-1279
11. Kaff V., Hicks R.J., MacManus M.P., et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 19 (2001) 111-118
12. Sachs S., and Bilfinger T.V. The impact of positron emission tomography on clinical decision making in a University-based multidisciplinary lung cancer practice. Chest 128 (2005) 698-703
13. Wiering B., Krabbe P.F., Pager G.J., Oyen W.J., and Ruers T.J. The impact of fluor-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104 (2005) 2658-2670
14. Dizendorf E.V., Baumert B.G., von Schulthess G.K., Lütolf U.M., and Steinert H.C. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44 (2003) 24-29
15. Hoekstra C.J., Paglianiti I., Hoekstra O.S., et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27 (2000) 731-743
16. Klaeser B., Wiederkehr O., Koeberle D., Mueller A., Bubeck B., and Thuerlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 18 (2007) 1329-1334
17. Dilhuydy M.S., Durieux A., Pariente A., et al. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation. Oncology 70 (2006) 339-344
18. Hillner B.E., Tunuguntla R., and Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 22 (2004) 4147-4156
19. Schwartz D.L., Ford E., Raiendran J., et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 129-136
20. Keidar Z., Haim N., Guralnik L., et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 45 (2004) 1640-1646
21. Fryback D.G., and Thornbury J.R. The efficacy of diagnostic imaging. Med Decis Making 11 (1991) 88-94